Cost of Revenue: Key Insights for Pfizer Inc. and Exelixis, Inc.

Cost of Revenue: A Comparative Analysis of Pfizer Inc. and Exelixis, Inc.

In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. Over the past decade, Pfizer Inc. and Exelixis, Inc. have shown distinct trajectories in their cost of revenue, reflecting their unique market strategies and operational scales.

Pfizer Inc.: A Giant's Journey

Pfizer, a global leader, has consistently maintained a high cost of revenue, peaking in 2022 with a staggering 34 billion USD. This represents a 258% increase from 2014, highlighting its expansive growth and investment in research and development.

Exelixis, Inc.: A Rising Star

In contrast, Exelixis, a smaller biotech firm, has seen its cost of revenue grow by over 3,450% from 2014 to 2023. This dramatic rise underscores its aggressive expansion and increasing market presence.

Both companies illustrate the diverse paths within the pharmaceutical sector, offering valuable insights into their operational strategies and market dynamics.